{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:00:36Z","timestamp":1786719636627,"version":"build-2736575974"},"reference-count":165,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K99 CA212302-01A1"],"award-info":[{"award-number":["K99 CA212302-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001787","name":"Parker Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2018,9,2]]},"DOI":"10.1080\/10428194.2017.1403024","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T09:29:20Z","timestamp":1511342960000},"page":"2040-2055","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies"],"prefix":"10.1080","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-5793","authenticated-orcid":false,"given":"Antonia","family":"Rotolo","sequence":"first","affiliation":[{"name":"Department of Medicine, Hammersmith Hospital, Imperial College London, Centre for Haematology","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-9780","authenticated-orcid":false,"given":"Anastasios","family":"Karadimitris","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hammersmith Hospital, Imperial College London, Centre for Haematology","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine at the University of Pennsylvania, Center for Cellular Immunotherapies","place":["Philadelphia, USA"]},{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania","place":["Philadelphia, USA"]},{"name":"Abramson Cancer Center, University of Pennsylvania","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0336-z"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(87)90502-X"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.36"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1182\/blood.V128.22.998.998","article-title":"A phase 2 multicenter trial of KTE-C19 (anti-CD19 CAR T Cells) in patients with chemorefractory primary mediastinal B-Cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL): interim results from ZUMA-1","volume":"128","author":"Neelapu SS","year":"2016","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et\u00a0al. A phase 2 multicenter trial of KTE-C19 (anti-CD19 CAR T Cells) in patients with chemorefractory primary mediastinal B-Cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL): interim results from ZUMA-1. Blood. 2016;128:998.","journal-title":"Blood"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"e_1_3_2_15_1","unstructured":"SEER Cancer Statistics Review 1975\u20132013 National Cancer Institute. Bethesda MD [Internet]. Updated September 12 2016 based on November 2015 SEER data submission posted to the SEER web site April 2016 [cited March 2017]. Available from: http:\/\/seer.cancer.gov\/csr\/1975_2013\/."},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481302000108"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328343b858"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2010.162"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.934"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110313251802"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.04.027"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.12.496"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703895"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.3.649.649"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.23.4314"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-604520"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2004.1.80"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.10.004"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carres.2008.01.009"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047399"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.03.022"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1309\/E36008Y2H08Q1AYY"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2325"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409049629"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.01.025"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.4.527"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210364"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.52"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.164"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529537"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-575704"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.2316.2316"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.120.120"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474056"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12282"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.62"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.12.003"},{"key":"e_1_3_2_49_1","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood.V126.23.3778.3778","article-title":"First-in-man CD123-specific chimeric antigen receptor-modified T cells for the treatment of refractory acute myeloid leukemia","volume":"126","author":"Luo Y","year":"2015","unstructured":"Luo Y, Chang L-J, Hu Y, et\u00a0al. First-in-man CD123-specific chimeric antigen receptor-modified T cells for the treatment of refractory acute myeloid leukemia. Blood. 2015;126:3778\u20133778.","journal-title":"Blood"},{"key":"e_1_3_2_50_1","unstructured":"Cellectis Press Release. Cellectis submits an application for UCART123 an allogeneic gene edited CAR T-cell product candidate in AML and BPDCN. New York; [Internet]. 2017. Available from: https:\/\/www.cellectis.com\/en\/content\/cellectis-submits-ind-application-ucart123-allogeneic-gene-edited-car-t-cell-product-0."},{"key":"e_1_3_2_51_1","article-title":"Cd123 specific chimeric antigen receptors for cancer immunotherapy","author":"Galetto R.","year":"2015","unstructured":"Galetto R. Cd123 specific chimeric antigen receptors for cancer immunotherapy. Google Patents WO2015140268A1; 2015.","journal-title":"Google Patents"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-083048"},{"key":"e_1_3_2_53_1","doi-asserted-by":"crossref","unstructured":"Kenderian SS Ruella M Shestova O et\u00a0al. 766. Leukemia stem cells are characterised by CLEC12A expression and chemotherapy refractoriness that can be overcome by targeting with chimeric antigen receptor T cells. ASH Annual Meeting San Diego; 2016.","DOI":"10.1182\/blood.V128.22.766.766"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.05.024"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.092"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504312102"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.21"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.154"},{"key":"e_1_3_2_59_1","first-page":"8","article-title":"NKG2D ligands as therapeutic targets","volume":"13","author":"Spear P","year":"2013","unstructured":"Spear P, Wu MR, Sentman ML, et\u00a0al. NKG2D ligands as therapeutic targets. Cancer Immun. 2013;13:8.","journal-title":"Cancer Immun"},{"key":"e_1_3_2_60_1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood.V122.21.605.605","article-title":"CD44v6 is required for in vivo tumorigenesis of human AML and MM cells: role of microenvironmental signals and therapeutic implications","volume":"122","author":"Casucci M","year":"2013","unstructured":"Casucci M, Falcone L, Camisa B, et\u00a0al. CD44v6 is required for in vivo tumorigenesis of human AML and MM cells: role of microenvironmental signals and therapeutic implications. Blood. 2013;122:605.","journal-title":"Blood"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.194"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1072.1072"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761320"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3143131.x"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595801"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051914-021702"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000166"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199911000-00001"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-059139"},{"key":"e_1_3_2_70_1","doi-asserted-by":"crossref","unstructured":"Nikiforow S Werner L Murad J et\u00a0al. Safety data from a first-in-human phase 1 trial of NKG2D chimeric antigen receptor-T cells in AML\/MDS and multiple myeloma. ASH Annual Meeting San Diego; 2016.","DOI":"10.1182\/blood.V128.22.4052.4052"},{"key":"e_1_3_2_71_1","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1182\/blood.V128.22.4058.4058","article-title":"Chimeric antigen receptor-modified T cells for the treatment of acute myeloid leukemia expressing CD33","volume":"128","author":"Song D","year":"2016","unstructured":"Song D, Swartz MH, Biesecker SG, et\u00a0al. Chimeric antigen receptor-modified T cells for the treatment of acute myeloid leukemia expressing CD33. Blood. 2016;128:4058.","journal-title":"Blood"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0378-7"},{"key":"e_1_3_2_73_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.V126.23.185.185","article-title":"Chimeric T cells for therapy of CD30+ Hodgkin and non-Hodgkin lymphomas","volume":"126","author":"Ramos CA","year":"2015","unstructured":"Ramos CA, Ballard B, Liu E, et\u00a0al. Chimeric T cells for therapy of CD30+ Hodgkin and non-Hodgkin lymphomas. Blood. 2015;126:185.","journal-title":"Blood"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(16)34024-2"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1365"},{"key":"e_1_3_2_76_1","unstructured":"Kochenderfer JN. Anti-CD30 chimeric antigen receptors. Google Patents WO2017066122 A1; 2017."},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA3001"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3010"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2127.2127"},{"key":"e_1_3_2_81_1","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1182\/blood.V128.22.4557.4557","article-title":"Development of novel non-immunoglobulin centyrin-based cars (CARTyrins) targeting human BCMA","volume":"128","author":"Barnett BE","year":"2016","unstructured":"Barnett BE, Wang X, Hermanson DL, et\u00a0al. Development of novel non-immunoglobulin centyrin-based cars (CARTyrins) targeting human BCMA. Blood. 2016;128:4557.","journal-title":"Blood"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocit.2014.11.001"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504542"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.974.974"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.12.009"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13976"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4463"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.77"},{"key":"e_1_3_2_90_1","volume-title":"Chimeric antigen receptor. Google Patents","author":"Pul\u00e9 M","year":"2015","unstructured":"Pul\u00e9 M, Yong K, Lee L, et al. Chimeric antigen receptor. Google Patents PCT\/GB2014\/053058; 2015."},{"key":"e_1_3_2_91_1","doi-asserted-by":"crossref","unstructured":"Lee SHL Draper BO Chaplin N et\u00a0al. An APRIL based chimeric antigen receptor to simultaneously target BCMA and TACI in multiple myeloma (MM) has potent activity in vitro and in vivo. ASH Annual Meeting San Diego; 2016.","DOI":"10.1182\/blood.V128.22.379.379"},{"key":"e_1_3_2_92_1","volume-title":"Chimeric antigen receptors targeting b-cell maturation antigen. Google Patents","author":"Kochenderfer JN.","year":"2013","unstructured":"Kochenderfer JN. Chimeric antigen receptors targeting b-cell maturation antigen. Google Patents; 2013."},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4512"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12563"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.974.974"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-183772"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716652862"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.279"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2510"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.07.167"},{"key":"e_1_3_2_105_1","unstructured":"Juillerat A Valton J Gautron A et\u00a0al. Targeted genome modifications for improved adoptive immunotherapy Chimeric Antigen Receptor Therapy in Haematology and Oncology: Current Successes and Challenges. London 2015 P006; 2015."},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1217374"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0373-2"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21373"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059636"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166891"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-736041"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.016"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4077"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0043"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(16)33082-9"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.154"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0139"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0159"},{"key":"e_1_3_2_120_1","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1182\/blood.V128.22.2163.2163","article-title":"Balance of anti-CD123 chimeric antigen receptor (CAR) binding affinity and density for the treatment of acute myeloid leukemia","volume":"128","author":"Arcangeli S","year":"2016","unstructured":"Arcangeli S, Bardelli M, Rotiroti MC, et\u00a0al. Balance of anti-CD123 chimeric antigen receptor (CAR) binding affinity and density for the treatment of acute myeloid leukemia. Blood. 2016;128:2163.","journal-title":"Blood"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.04.017"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159477"},{"key":"e_1_3_2_123_1","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1182\/blood.V128.22.2170.2170","article-title":"Reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"128","author":"Drent E","year":"2016","unstructured":"Drent E, Themeli M, Poels R, et\u00a0al. Reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Blood. 2016;128:2170.","journal-title":"Blood"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2459"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0008"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9689-9"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.012"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1524155113"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040890"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20188"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.11.327"},{"key":"e_1_3_2_133_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.186.186"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3707"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11200"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405884101"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.6"},{"key":"e_1_3_2_138_1","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/blood.V124.21.2155.2155","article-title":"Engineered T cell receptor-mimic antibody (TCRm), chimeric antigen receptor (CAR) T cells against the intracellular protein Wilms tumor-1 (WT1) for treatment of hematologic and solid cancers","volume":"124","author":"Rafiq S","year":"2014","unstructured":"Rafiq S, Dao T, Liu C, et\u00a0al. Engineered T cell receptor-mimic antibody (TCRm), chimeric antigen receptor (CAR) T cells against the intracellular protein Wilms tumor-1 (WT1) for treatment of hematologic and solid cancers. Blood. 2014;124:2155.","journal-title":"Blood"},{"key":"e_1_3_2_139_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620715594736"},{"key":"e_1_3_2_140_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2012.48"},{"key":"e_1_3_2_141_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2016.1142868"},{"key":"e_1_3_2_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.07.002"},{"key":"e_1_3_2_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2014.08.001"},{"key":"e_1_3_2_144_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-493361"},{"key":"e_1_3_2_145_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_3_2_146_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2016.05.011"},{"key":"e_1_3_2_147_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"e_1_3_2_148_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.290.290"},{"key":"e_1_3_2_149_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2015.054"},{"key":"e_1_3_2_150_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209650"},{"key":"e_1_3_2_151_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32103"},{"key":"e_1_3_2_152_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907448106"},{"key":"e_1_3_2_153_1","doi-asserted-by":"crossref","unstructured":"Ruella M Klichinsky M Kenderian SS et\u00a0al. Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells. ASH Annual Meeting San Diego; 2016.","DOI":"10.1182\/blood.V128.22.43.43"},{"key":"e_1_3_2_154_1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V124.21.806.806","article-title":"Novel chimeric antigen receptor T cells for the treatment of Hodgkin lymphoma","volume":"124","author":"Ruella M","year":"2014","unstructured":"Ruella M, Kenderian SS, Shestova O, et\u00a0al. Novel chimeric antigen receptor T cells for the treatment of Hodgkin lymphoma. Blood. 2014;124:806.","journal-title":"Blood"},{"key":"e_1_3_2_155_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700664"},{"key":"e_1_3_2_156_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20150266"},{"key":"e_1_3_2_157_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.262"},{"key":"e_1_3_2_158_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87366"},{"key":"e_1_3_2_159_1","unstructured":"Ma Y Pinz K Jiang X et\u00a0al. Chimeric antigen receptors (CARs) compositions and methods of use thereof. Google Patents WO2016210293 A1; 2016."},{"key":"e_1_3_2_160_1","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.32"},{"key":"e_1_3_2_161_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0231"},{"key":"e_1_3_2_162_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0423-1"},{"key":"e_1_3_2_163_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83416"},{"key":"e_1_3_2_164_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.61"},{"key":"e_1_3_2_165_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39"},{"key":"e_1_3_2_166_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.051169"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2017.1403024","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10428194.2017.1403024","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2017.1403024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:12:45Z","timestamp":1786716765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2017.1403024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":165,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,2]]}},"alternative-id":["10.1080\/10428194.2017.1403024"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2017.1403024","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}